Date: 2014-04-03
Type of information: Services contract
Compound: molecular signature for hepatocellular carcinoma
Company: Integragen (France) Pfizer (USA - NY)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease: hepatocellular carcinoma
Details: * On April 3, 2014, IntegraGen, a French player in the development and marketing of molecular diagnostic testing in oncology and autism, has announced that it has entered into an agreement with Pfizer that provides Pfizer access to evaluate the company’s proprietary molecular signature for hepatocellular carcinoma. The 56-gene molecular signature covered by the agreement is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and subcategorize patients into six separate classifications based on the molecular characteristics of their liver tumors. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
